Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma Journal Article
| Authors: | Zelefsky, M. J.; Greco, C.; Motzer, R.; Magsanoc, J. M.; Pei, X.; Lovelock, M.; Mechalakos, J.; Zatcky, J.; Fuks, Z.; Yamada, Y. |
| Article Title: | Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma |
| Abstract: | Purpose: To report tumor local progression-free outcomes after treatment with single-dose, image-guided, intensity-modulated radiotherapy and hypofractionated regimens for extracranial metastases from renal cell primary tumors. Patients and Methods: Between 2004 and 2010, 105 lesions from renal cell carcinoma were treated with either single-dose, image-guided, intensity-modulated radiotherapy to a prescription dose of 18-24 Gy (median, 24) or hypofractionation (three or five fractions) with a prescription dose of 20-30 Gy. The median follow-up was 12 months (range, 1-48). Results: The overall 3-year actuarial local progression-free survival for all lesions was 44%. The 3-year local progression-free survival for those who received a high single-dose (24 Gy; n = 45), a low single-dose (<24 Gy; n = 14), or hypofractionation regimens (n = 46) was 88%, 21%, and 17%, respectively (high single dose vs. low single dose, p = .001; high single dose vs. hypofractionation, p < .001). Multivariate analysis revealed the following variables were significant predictors of improved local progression-free survival: 24 Gy dose compared with a lower dose (p = .009) and a single dose vs. hypofractionation (p = .008). Conclusion: High single-dose, image-guided, intensity-modulated radiotherapy is a noninvasive procedure resulting in high probability of local tumor control for metastatic renal cell cancer generally considered radioresistant according to the classic radiobiologic ranking. © 2012 Elsevier Inc. |
| Keywords: | controlled study; debridement; fracture; major clinical study; intensity modulated radiation therapy; bone metastasis; radiation dose; outcome assessment; follow up; cytology; progression free survival; radiotherapy; pathology; radiation injury; prediction; kidney carcinoma; renal cell cancer; tumors; radiation dose fractionation; erythema; cancer control; metastases; stereotactic body radiation therapy; hypofractionation; diseases; radiation dermatitis; renal cell; cells; image-guided radiotherapy; single fraction; image guided radiotherapy; noninvasive medical procedures |
| Journal Title: | International Journal of Radiation Oncology, Biology, Physics |
| Volume: | 82 |
| Issue: | 5 |
| ISSN: | 0360-3016 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2012-04-01 |
| Start Page: | 1744 |
| End Page: | 1748 |
| Language: | English |
| DOI: | 10.1016/j.ijrobp.2011.02.040 |
| PROVIDER: | scopus |
| PUBMED: | 21596489 |
| PMCID: | PMC4034682 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 11 May 2012" - "CODEN: IOBPD" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work